Evaluation of early and late toxicities in chemoradiation trials

Journal of Clinical Oncology

Volumn 25, Issue 26, 2007, Pages 4096-4103

  Bentzen, Søren M ^a   Trotti, Andrea ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARMUSTINE; CETUXIMAB; CISPLATIN; IMATINIB; TRASTUZUMAB;

ACNE; ALOPECIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; GLIOBLASTOMA; HEAD AND NECK CANCER; HEARING LOSS; HEART FAILURE; HUMAN; INCIDENCE; INJECTION SITE REACTION; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; PATIENT COMPLIANCE; PERCEPTION DEAFNESS; PRIORITY JOURNAL; RADIATION INJURY; RECTUM DISEASE; REVIEW; SIDE EFFECT; SOLID TUMOR; SURVIVAL TIME; WEIGHT REDUCTION; HEAD AND NECK TUMOR; METHODOLOGY; MULTIMODALITY CANCER THERAPY; RADIOTHERAPY; RISK ASSESSMENT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; RADIOTHERAPY; RISK ASSESSMENT;

EID: 34748907886     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.3983     Document Type: Review

References (67)

1. Trotti A, Pajak TF, Gwede CK, et al: TAME: Development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol 8:613-624, 2007
2. Centers for Disease Control and Prevention: Cancer survivorship-United States, 1971-2001. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5324a3.htm
3. Yabroff KR, Lawrence WF, Clauser S, et al: Burden of illness in cancer survivors: Findings from a population-based national sample. J Natl Cancer Inst 96:1322-1330, 2004
4. Bentzen SM, Overgaard M: Clinical radiobiology and normal-tissue morbidity after breast cancer treatment, in Altman KI, Lett JT (eds): Advances in Radiation Biology, Volume 18. San Diego, CA, Academic Press, 1994, pp 25-51
5. List MA, Bilir SP: Evaluations of quality of life and organ function. Semin Oncol 31:827-835, 2004
6. Hawkins MM: Long-term survivors of childhood cancers: What knowledge have we gained? Nat Clin Pract Oncol 1:26-31, 2004
7. Bentzen SM: Preventing or reducing late side effects of radiation therapy: Radiobiology meets molecular pathology. Nat Rev Cancer 6:702-713, 2006
8. Dorr W, Hendry JH: Consequential late effects in normal tissues. Radiother Oncol 61:223-231, 2001
9. Ioannidis JP, Lau J: Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas. JAMA 285:437-443, 2001
10. Trotti A, Bentzen SM: The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol 22:19-22, 2004
11. Trotti A, Colevas AD, Setser A, et al: Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol (in press)
12. Bentzen SM, Harari PM, Bernier J: Exploitable mechanisms for combining drugs with radiation: Concepts, achievements and future directions. Nat Clin Pract Oncol 4:172-180, 2007
13. Wilson GD, Bentzen SM, Harari PM: Biologic basis for combining drugs with radiation. Semin Radiat Oncol 16:2-9, 2006
14. Seiwert TY, Salama JK, Vokes EE: The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 4:156-171, 2007
15. Hao D, Ritter MA, Oliver T, et al: Platinum-based concurrent chemoradiotherapy for tumors of the head and neck and the esophagus. Semin Radiat Oncol 16:10-19, 2006
16. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data - MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949-955, 2000
17. Bernier J, Bentzen SM: Altered fractionation and combined radio-chemotherapy approaches: Pioneering new opportunities in head and neck oncology. Eur J Cancer 39:560-571, 2003
18. Bernier J: Alteration of radiotherapy fractionation and concurrent chemotherapy: A new frontier in head and neck oncology? Nat Clin Pract Oncol 2:305-314, 2005
19. Eisbruch A, Lyden T, Bradford CR, et al: Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 53:23-28, 2002
20. Nguyen NP, Moltz CC, Frank C, et al: Dysphagia following chemoradiation for locally advanced head and neck cancer. Ann Oncol 15:383-388, 2004
21. Frowen JJ, Perry AR: Swallowing outcomes after radiotherapy for head and neck cancer: A systematic review. Head Neck 28:932-944, 2006
22. Kotz T, Costello R, Li Y, et al: Swallowing dysfunction after chemoradiation for advanced squamous cell carcinoma of the head and neck. Head Neck 26:365-372, 2004
23. Honore HB, Bentzen SM, Moller K, et al: Sensorineural hearing loss after radiotherapy for nasopharyngeal carcinoma: Individualized risk estimation. Radiother Oncol 65:9-16, 2002
24. Low WK, Toh ST, Wee J, et al: Sensorineural hearing loss after radiotherapy and chemoradiotherapy: A single, blinded, randomized study. J Clin Oncol 24:1904-1909, 2006
25. Chen WC, Jackson A, Budnick AS, et al: Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer 106:820-829, 2006
26. Rischin D, Corry J, Smith J, et al: Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol 20:1845-1852, 2002
27. Bentzen SM, Rosenthal DI, Weymuller E, et al: Increasing toxicity in non-operative head and neck cancer treatment: Investigations and interventions. Int J Radiat Oncol Biol Phys (in press)
28. Bentzen SM: Radiation therapy: Intensity modulated, image guided, biologically optimized and evidence based. Radiother Oncol 77:227-230, 2005
29. Bentzen SM: Theragnostic imaging for radiation oncology: Dose-painting by numbers. Lancet Oncol 6:112-117, 2005
30. Chien KR: Herceptin and the heart: A molecular modifier of cardiac failure. N Engl J Med 354:789-790, 2006
31. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006
32. Kerkela R, Grazette L, Yacobi R, et al: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908-916, 2006
33. Berman E, Nicolaides M, Maki RG, et al: Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354:2006-2013, 2006
34. Hurwitz H, Saini S: Bevacizumab in the treatment of metastatic colorectal cancer: Safety profile and management of adverse events. Semin Oncol 33:S26-S34, 2006 (suppl 10)
35. Kilickap S, Abali H, Celik I: Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 21:3542, 2003
36. Verheul HM, Pinedo HM: Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7:475-485, 2007
37. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006
38. Radiation Therapy Oncology Group: A phase II randomized trial of surgery followed by chemoradiotherapy plus C225 (cetuximab) for advanced squamous cell carcinoma of the head and neck. http://www.rtog.org/members/protocols/0234/0234. pdf
39. Radiation Therapy Oncology Group: A phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab (C225) [followed by surgery for selected patients] for stage III and IV head and neck carcinomas. http://www.rtog.org/members/ protocols/0522/0522.pdf
40. Trotti A: Toxicity in head and neck cancer: A review of trends and issues. Int J Radiat Oncol Biol Phys 47:1-12, 2000
41. Gwede C, Saranga S, Lee J, et al: Variations in adverse event reporting in phase III head and neck trials (1990 to 2003): A systematic review. Int J Radiat Oncol Biol Phys 62:S352, 2007 (suppl 1)
42. Bieri S, Bentzen SM, Huguenin P, et al: Early morbidity after radiotherapy with or without chemotherapy in advanced head and neck cancer: Experience from four nonrandomized studies. Strahlenther Onkol 179:390-395, 2003
43. Lee NY, O'Meara W, Chan K, et al: Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys [epub ahead of print on May 8, 2007]
44. Trotti A, Garden A, Warde P, et al: A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys 58:674-681, 2004
45. Dische S, Saunders MI, Barrett A, et al: A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 44:123-136, 1997
46. Bentzen SM, Saunders MI, Dische S, et al: Radiotherapy-related early morbidity in head and neck cancer: Quantitative clinical radiobiology as deduced from the CHART trial. Radiother Oncol 60:123-135, 2001
47. Mahoney MR, Sargent DJ, O'Connell MJ, et al: Dealing with a deluge of data: An assessment of adverse event data on North Central Cancer Treatment Group trials. J Clin Oncol 23:9275-9281, 2005
48. Bentzen SM, Dorr W, Anscher MS, et al: Normal tissue effects: Reporting and analysis. Semin Radiat Oncol 13:189-202, 2003
49. Bent S, Padula A, Avins AL: Brief communication: Better ways to question patients about adverse medical events - A randomized, controlled trial. Ann Intern Med 144:257-261, 2006
50. Ioannidis JP, Mulrow CD, Goodman SN: Adverse events: The more you search, the more you find. Ann Intern Med 144:298-300, 2006
51. Morse MA, Califf RM, Sugarman J: Monitoring and ensuring safety during clinical research. JAMA 285:1201-1205, 2001
52. Wallin J, Sjovall J: Detection of adverse drug reactions in a clinical trial using two types of questioning. Clin Ther 3:450-452, 1981
53. Fromme EK, Eilers KM, Mori M, et al: How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 22:3485-3490, 2004
54. Calais G, Alfonsi M, Bardet E, et al: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91:2081-2086, 1999
55. Denis F, Garaud P, Bardet E, et al: Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22:69-76, 2004
56. Denis F, Garaud P, Bardet E, et al: Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: Comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 55:93-98, 2003
57. Bentzen SM, Vaeth M, Pedersen D, et al: Why actuarial estimates should be used in reporting late normal-tissue effects of cancer treatment. . .now!. Int J Radiat Oncol Biol Phys 32:1531-1534, 1995
58. Khalil AA, Bentzen SM, Bernier J, et al: Compliance to the prescribed dose and overall treatment time in five randomized clinical trials of altered fractionation in radiotherapy for head-and-neck carcinomas. Int J Radiat Oncol Biol Phys 55:568-575, 2003
59. Buckner JC, Ballman KV, Michalak JC, et al: Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. J Clin Oncol 24:3871-3879, 2006
60. Hanlon AL, Schultheiss TE, Hunt MA, et al: Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales. Int J Radiat Oncol Biol Phys 38:59-63, 1997
61. Tucker SL, Dong L, Cheung R, et al: Comparison of rectal dose-wall histogram versus dose-volume histogram for modeling the incidence of late rectal bleeding after radiotherapy. Int J Radiat Oncol Biol Phys 60:1589-1601, 2004
62. Li C, Wilson PB, Levine E, et al: TGF-beta1 levels in pre-treatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis. Int J Cancer 84:155-159, 1999
63. Anscher MS, Marks LB, Shafman TD, et al: Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation. J Clin Oncol 19:3758-3765, 2001
64. Andreassen CN: Can risk of radiotherapy-induced normal tissue complications be predicted from genetic profiles? Acta Oncol 44:801-815, 2005
65. West CM, McKay MJ, Holscher T, et al: Molecular markers predicting radiotherapy response: Report and recommendations from an International Atomic Energy Agency technical meeting. Int J Radiat Oncol Biol Phys 62:1264-1273, 2005
66. Bentzen SM, Overgaard J: Patient-to-patient variability in the expression of radiation-induced normal-tissue injury. Semin Radiat Oncol 4:68-80, 1994
67. Safwat A, Bentzen SM, Turesson I, et al: Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy. Int J Radiat Oncol Biol Phys 52:198-204, 2002